Randomized, Double-Blind, Phase I Pharmacokinetic Study of Subcutaneous Recombinant Human Superoxide Dismutase (rhSOD) in Healthy Volunteers
These findings suggest that subcutaneous rhSOD may be a promising therapeutic candidate for conditions characterized by excessive <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:msubsup><mml:mtext>O</mml:mtext> <mml:mrow><mml:mn>2</mml:mn></mml:mrow> <mml:mrow><mml:mo>·</mml:mo> <mml:mo>-</mml:mo></mml:mrow> </mml:msubsup> </mml:math> exposure or diminished endogenous SOD activity. Further clinical studies are warranted to assess its anti-inflammatory potential in relevant patient populations. EudraCT Number: 2022-000173-11.
Authors
- Brigitta Vcelar
- Dietmar Katinger (ORCID: https://orcid.org/0000-0002-0536-3148)
- Richard Partl (ORCID: https://orcid.org/0000-0001-9132-012X)
- Martin Bauer (ORCID: https://orcid.org/0000-0003-4818-1560)
- Harald Schnidar (ORCID: https://orcid.org/0000-0002-2280-8161)
- Valentin al Jalali (ORCID: https://orcid.org/0000-0002-9196-1936)
- Michael Wölfl‐Duchek
- Rawad Bashur
- F. Bergmann
Institutions
- Medical University of Graz (AT)
- Vienna General Hospital (AT)
- Polymun (Austria) (AT)
- Vienna Consulting Engineers (Austria) (AT)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Clinical Pharmacokinetics
- Published
- 2025-10-18
- DOI
- https://doi.org/10.1007/s40262-025-01578-1
- Citations
- 1
- Primary Topic
- Vitamin C and Antioxidants Research
- Type
- article
- Field-Weighted Citation Impact
- 1.12
Funders
- Österreichische Forschungsförderungsgesellschaft